1
|
Zha J, He J, Wu C, Zhang M, Liu X, Zhang J. Designing drugs and chemical probes with the dualsteric approach. Chem Soc Rev 2023; 52:8651-8677. [PMID: 37990599 DOI: 10.1039/d3cs00650f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2023]
Abstract
Traditionally, drugs are monovalent, targeting only one site on the protein surface. This includes orthosteric and allosteric drugs, which bind the protein at orthosteric and allosteric sites, respectively. Orthosteric drugs are good in potency, whereas allosteric drugs have better selectivity and are solutions to classically undruggable targets. However, it would be difficult to simultaneously reach high potency and selectivity when targeting only one site. Also, both kinds of monovalent drugs suffer from mutation-caused drug resistance. To overcome these obstacles, dualsteric modulators have been proposed in the past twenty years. Compared to orthosteric or allosteric drugs, dualsteric modulators are bivalent (or bitopic) with two pharmacophores. Each of the two pharmacophores bind the protein at the orthosteric and an allosteric site, which could bring the modulator with special properties beyond monovalent drugs. In this study, we comprehensively review the current development of dualsteric modulators. Our main effort reason and illustrate the aims to apply the dualsteric approach, including a "double win" of potency and selectivity, overcoming mutation-caused drug resistance, developments of function-biased modulators, and design of partial agonists. Moreover, the strengths of the dualsteric technique also led to its application outside pharmacy, including the design of highly sensitive fluorescent tracers and usage as molecular rulers. Besides, we also introduced drug targets, designing strategies, and validation methods of dualsteric modulators. Finally, we detail the conclusions and perspectives.
Collapse
Affiliation(s)
- Jinyin Zha
- College of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
- State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jixiao He
- State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Chengwei Wu
- State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Mingyang Zhang
- State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Xinyi Liu
- College of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
- State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jian Zhang
- College of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
- State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Medicinal Chemistry and Bioinformatics Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
2
|
Dolejší E, Szánti-Pintér E, Chetverikov N, Nelic D, Randáková A, Doležal V, Kudová E, Jakubík J. Neurosteroids and steroid hormones are allosteric modulators of muscarinic receptors. Neuropharmacology 2021; 199:108798. [PMID: 34555368 DOI: 10.1016/j.neuropharm.2021.108798] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 09/07/2021] [Accepted: 09/16/2021] [Indexed: 11/17/2022]
Abstract
The membrane cholesterol was found to bind and modulate the function of several G-protein coupled receptors including muscarinic acetylcholine receptors. We investigated the binding of 20 steroidal compounds including neurosteroids and steroid hormones to muscarinic receptors. Corticosterone, progesterone and some neurosteroids bound to muscarinic receptors with the affinity of 100 nM or greater. We established a structure-activity relationship for steroid-based allosteric modulators of muscarinic receptors. Further, we show that corticosterone and progesterone allosterically modulate the functional response of muscarinic receptors to acetylcholine at physiologically relevant concentrations. It can play a role in stress control or in pregnancy, conditions where levels of these hormones dramatically oscillate. Allosteric modulation of muscarinic receptors via the cholesterol-binding site represents a new pharmacological approach at diseases associated with altered cholinergic signalling.
Collapse
Affiliation(s)
- Eva Dolejší
- Institute of Physiology Czech Academy of Sciences, Prague, Czech Republic
| | - Eszter Szánti-Pintér
- Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences, Prague, Czech Republic
| | | | - Dominik Nelic
- Institute of Physiology Czech Academy of Sciences, Prague, Czech Republic
| | - Alena Randáková
- Institute of Physiology Czech Academy of Sciences, Prague, Czech Republic
| | - Vladimír Doležal
- Institute of Physiology Czech Academy of Sciences, Prague, Czech Republic
| | - Eva Kudová
- Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences, Prague, Czech Republic.
| | - Jan Jakubík
- Institute of Physiology Czech Academy of Sciences, Prague, Czech Republic.
| |
Collapse
|
3
|
Dolejší E, Chetverikov N, Szánti-Pintér E, Nelic D, Randáková A, Doležal V, El-Fakahany EE, Kudová E, Jakubík J. Neuroactive steroids, WIN-compounds and cholesterol share a common binding site on muscarinic acetylcholine receptors. Biochem Pharmacol 2021; 192:114699. [PMID: 34324870 DOI: 10.1016/j.bcp.2021.114699] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 07/20/2021] [Accepted: 07/20/2021] [Indexed: 02/06/2023]
Abstract
Endogenous neurosteroids and their synthetic analogues-neuroactive steroids-have been found to bind to muscarinic acetylcholine receptors and allosterically modulate acetylcholine binding and function. Using radioligand binding experiments we investigated their binding mode. We show that neuroactive steroids bind to two binding sites on muscarinic receptors. Their affinity for the high-affinity binding site is about 100 nM. Their affinity for the low-affinity binding site is about 10 µM. The high-affinity binding occurs at the same site as binding of steroid-based WIN-compounds that is different from the common allosteric binding site for alcuronium or gallamine that is located between the second and third extracellular loop of the receptor. This binding site is also different from the allosteric binding site for the structurally related aminosteroid-based myorelaxants pancuronium and rapacuronium. Membrane cholesterol competes with neurosteroids/neuroactive steroids binding to both high- and low-affinity binding site, indicating that both sites are oriented towards the cell membrane..
Collapse
Affiliation(s)
- Eva Dolejší
- Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
| | | | - Eszter Szánti-Pintér
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
| | - Dominik Nelic
- Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
| | - Alena Randáková
- Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
| | - Vladimír Doležal
- Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
| | - Esam E El-Fakahany
- Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA
| | - Eva Kudová
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
| | - Jan Jakubík
- Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic.
| |
Collapse
|
4
|
Staszewski M, Nelic D, Jończyk J, Dubiel M, Frank A, Stark H, Bajda M, Jakubik J, Walczyński K. Guanidine Derivatives: How Simple Structural Modification of Histamine H 3R Antagonists Has Led to the Discovery of Potent Muscarinic M 2R/M 4R Antagonists. ACS Chem Neurosci 2021; 12:2503-2519. [PMID: 34100603 PMCID: PMC8291587 DOI: 10.1021/acschemneuro.1c00237] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
![]()
This article describes
the discovery of novel potent muscarinic
receptor antagonists identified during a search for more active histamine
H3 receptor (H3R) ligands. The idea was to replace
the flexible seven methylene linker with a semirigid 1,4-cyclohexylene
or p-phenylene substituted group of the previously
described histamine H3R antagonists ADS1017 and ADS1020. These simple structural modifications
of the histamine H3R antagonist led to the emergence of
additional pharmacological effects, some of which unexpectedly showed
strong antagonist potency at muscarinic receptors. This paper reports
the routes of synthesis and pharmacological characterization of guanidine
derivatives, a novel chemotype of muscarinic receptor antagonists
binding to the human muscarinic M2 and M4 receptors
(hM2R and hM4R, respectively) in nanomolar concentration
ranges. The affinities of the newly synthesized ADS10227 (1-{4-{4-{[4-(phenoxymethyl)cyclohexyl]methyl}piperazin-1-yl}but-1-yl}-1-(benzyl)guanidine)
at hM2R and hM4R were 2.8 nM and 5.1 nM, respectively.
Collapse
Affiliation(s)
- Marek Staszewski
- Department of Synthesis and Technology of Drugs, Medical University of Lodz, ul. Muszyńskiego 1, 90-151 Łódź, Poland
| | - Dominik Nelic
- Department of Neurochemistry, Institute of Physiology CAS, Videnska 1083, CZ142 20, Prague, Czech Republic
| | - Jakub Jończyk
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Mariam Dubiel
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, Duesseldorf 40225, Germany
| | - Annika Frank
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, Duesseldorf 40225, Germany
| | - Holger Stark
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, Duesseldorf 40225, Germany
| | - Marek Bajda
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Jan Jakubik
- Department of Neurochemistry, Institute of Physiology CAS, Videnska 1083, CZ142 20, Prague, Czech Republic
| | - Krzysztof Walczyński
- Department of Synthesis and Technology of Drugs, Medical University of Lodz, ul. Muszyńskiego 1, 90-151 Łódź, Poland
| |
Collapse
|
5
|
Randáková A, Nelic D, Doležal V, El-Fakahany EE, Boulos J, Jakubík J. Agonist-Specific Conformations of the M 2 Muscarinic Acetylcholine Receptor Assessed by Molecular Dynamics. J Chem Inf Model 2020; 60:2325-2338. [PMID: 32130001 DOI: 10.1021/acs.jcim.0c00041] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Binding of muscarinic ligands, both antagonists and agonists, and their effects on the conformation of the M2 acetylcholine receptor were modeled in silico and compared to experimental data. After docking of antagonists to the M2 receptor in an inactive conformation (3UON, 5ZK3, 5ZKB, or 5ZKB) and agonists in an active conformation (4MQS), 100 ns of conventional molecular dynamics (MD) followed by 500 ns of accelerated MD was run. Conventional MD revealed ligand-specific interactions with the receptor. Antagonists stabilized the receptor in an inactive conformation during accelerated MD. The receptor in complex with various agonists attained different conformations specific to individual agonists. The magnitude of the TM6 movement correlated with agonist efficacy at the non-preferential Gs pathway. The shape of the intracellular opening where the receptor interacts with a G-protein was different for the classical agonist carbachol, super-agonist iperoxo, and Gi/o-biased partial agonists JR-6 and JR-7, being compatible with experimentally observed agonist bias at the G-protein level. Moreover, a wash-resistant binding of the unique agonist xanomeline associated with interactions with membrane lipids was formed during accelerated MD. Thus, accelerated MD is suitable for modeling of ligand-specific receptor binding and receptor conformations that is essential for the design of experiments aimed at identification of the secondary binding sites and understanding molecular mechanisms underlying receptor activation.
Collapse
Affiliation(s)
- Alena Randáková
- Department of Neurochemistry, Institute of Physiology CAS, Prague, CZ 142 20, Czech Republic
| | - Dominik Nelic
- Department of Neurochemistry, Institute of Physiology CAS, Prague, CZ 142 20, Czech Republic
| | - Vladimír Doležal
- Department of Neurochemistry, Institute of Physiology CAS, Prague, CZ 142 20, Czech Republic
| | - Esam E El-Fakahany
- Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota 55455, United States
| | - John Boulos
- Department of Physical Sciences, Barry University, Miami Shores, Florida 33161, United States
| | - Jan Jakubík
- Department of Neurochemistry, Institute of Physiology CAS, Prague, CZ 142 20, Czech Republic
| |
Collapse
|
6
|
Randáková A, Nelic D, Ungerová D, Nwokoye P, Su Q, Doležal V, El-Fakahany EE, Boulos J, Jakubík J. Novel M 2 -selective, G i -biased agonists of muscarinic acetylcholine receptors. Br J Pharmacol 2020; 177:2073-2089. [PMID: 31910288 DOI: 10.1111/bph.14970] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 12/16/2019] [Accepted: 12/17/2019] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND AND PURPOSE More than 30% of currently marketed medications act via GPCRs. Thus, GPCRs represent one of the most important pharmacotherapeutic targets. In contrast to traditional agonists activating multiple signalling pathways, agonists activating a single signalling pathway represent a new generation of drugs with increased specificity and fewer adverse effects. EXPERIMENTAL APPROACH We have synthesized novel agonists of muscarinic ACh receptors and tested their binding and function (on levels of cAMP and inositol phosphates) in CHO cells expressing individual subtypes of muscarinic receptors, primary cultures of rat aortic smooth muscle cells and suspensions of digested native tissues from rats. Binding of the novel compounds to M2 receptors was modelled in silico. KEY RESULTS Two of the tested new compounds (1-(thiophen-2-ylmethyl)-3,6-dihydro-2H-pyridinium and 1-methyl-1-(thiophen-2-ylmethyl)-3,6-dihydro-2H-pyridinium) only inhibited cAMP synthesis in CHO cells, primary cultures, and native tissues, with selectivity for M2 muscarinic receptors and displaying bias towards the Gi signalling pathway at all subtypes of muscarinic receptors. Molecular modelling revealed interactions with the orthosteric binding site in a way specific for a given agonist followed by agonist-specific changes in the conformation of the receptor. CONCLUSIONS AND IMPLICATIONS The identified compounds may serve as lead structures in the search for novel non-steroidal and non-opioid analgesics acting via M2 and M4 muscarinic receptors with reduced side effects associated with activation of the phospholipase C signalling pathway.
Collapse
Affiliation(s)
- Alena Randáková
- Department of Neurochemistry, Institute of Physiology CAS, Prague, Czech Republic
| | - Dominik Nelic
- Department of Neurochemistry, Institute of Physiology CAS, Prague, Czech Republic
| | - Dana Ungerová
- Department of Neurochemistry, Institute of Physiology CAS, Prague, Czech Republic
| | - Peter Nwokoye
- Department of Physical Sciences, Barry University, Miami Shores, Florida
| | - Qiwen Su
- Department of Physical Sciences, Barry University, Miami Shores, Florida
| | - Vladimír Doležal
- Department of Neurochemistry, Institute of Physiology CAS, Prague, Czech Republic
| | - Esam E El-Fakahany
- Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota
| | - John Boulos
- Department of Physical Sciences, Barry University, Miami Shores, Florida
| | - Jan Jakubík
- Department of Neurochemistry, Institute of Physiology CAS, Prague, Czech Republic
| |
Collapse
|
7
|
Applications and limitations of fitting of the operational model to determine relative efficacies of agonists. Sci Rep 2019; 9:4637. [PMID: 30874590 PMCID: PMC6420642 DOI: 10.1038/s41598-019-40993-w] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Accepted: 02/27/2019] [Indexed: 02/02/2023] Open
Abstract
Proper determination of agonist efficacy is essential in the assessment of agonist selectivity and signalling bias. Agonist efficacy is a relative term that is dependent on the system in which it is measured, especially being dependent on receptor expression level. The operational model (OM) of functional receptor agonism is a useful means for the determination of agonist functional efficacy using the maximal response to agonist and ratio of agonist functional potency to its equilibrium dissociation constant (KA) at the active state of the receptor. However, the functional efficacy parameter τ is inter-dependent on two other parameters of OM; agonist’s KA and the highest response that could be evoked in the system by any stimulus (EMAX). Thus, fitting of OM to functional response data is a tricky process. In this work we analyse pitfalls of fitting OM to experimental data and propose a rigorous fitting procedure where KA and EMAX are derived from half-efficient concentration of agonist and apparent maximal responses obtained from a series of functional response curves. Subsequently, OM with fixed KA and EMAX is fitted to functional response data to obtain τ. The procedure was verified at M2 and M4 muscarinic receptors fused with the G15 G-protein α-subunit. The procedure, however, is applicable to any receptor-effector system.
Collapse
|
8
|
Randáková A, Rudajev V, Doležal V, Boulos J, Jakubík J. Novel long-acting antagonists of muscarinic ACh receptors. Br J Pharmacol 2018; 175:1731-1743. [PMID: 29498041 PMCID: PMC5913398 DOI: 10.1111/bph.14187] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Revised: 01/24/2018] [Accepted: 02/15/2018] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND AND PURPOSE The aim of this study was to develop potent and long-acting antagonists of muscarinic ACh receptors. The 4-hexyloxy and 4-butyloxy derivatives of 1-[2-(4-oxidobenzoyloxy)ethyl]-1,2,3,6-tetrahydropyridin-1-ium were synthesized and tested for biological activity. Antagonists with long-residence time at receptors are therapeutic targets for the treatment of several neurological and psychiatric human diseases. Their long-acting effects allow for reduced daily doses and adverse effects. EXPERIMENTAL APPROACH The binding and antagonism of functional responses to the agonist carbachol mediated by 4-hexyloxy compounds were investigated in CHO cells expressing individual subtypes of muscarinic receptors and compared with 4-butyloxy analogues. KEY RESULTS The 4-hexyloxy derivatives were found to bind muscarinic receptors with micromolar affinity and antagonized the functional response to carbachol with a potency ranging from 30 nM at M1 to 4 μM at M3 receptors. Under washing conditions to reverse antagonism, the half-life of their antagonistic action ranged from 1.7 h at M2 to 5 h at M5 receptors. CONCLUSIONS AND IMPLICATIONS The 4-hexyloxy derivatives were found to be potent long-acting M1 -preferring antagonists. In view of current literature, M1 -selective antagonists may have therapeutic potential for striatal cholinergic dystonia, delaying epileptic seizure after organophosphate intoxication or relieving depression. These compounds may also serve as a tool for research into cognitive deficits.
Collapse
Affiliation(s)
- Alena Randáková
- Department of Neurochemistry, Institute of PhysiologyCzech Academy of SciencesPragueCzech Republic
| | - Vladimír Rudajev
- Department of Neurochemistry, Institute of PhysiologyCzech Academy of SciencesPragueCzech Republic
| | - Vladimír Doležal
- Department of Neurochemistry, Institute of PhysiologyCzech Academy of SciencesPragueCzech Republic
| | - John Boulos
- Department of Physical SciencesBarry UniversityMiami ShoresFLUSA
| | - Jan Jakubík
- Department of Neurochemistry, Institute of PhysiologyCzech Academy of SciencesPragueCzech Republic
| |
Collapse
|